BioSpace News Archive

Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn.

Evaxion has hired a new CEO to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that company executives will participate in three upcoming healthcare investment conferences.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.

Citryll announced the appointment of Eduardo Bravo as Chief Executive Officer.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023.

Aryastha Life Sciences, a leading Contract Research and Development Organization in healthcare, has achieved a major milestone by successfully concluding its Series A funding with significant backing from Vessella Group, a prominent investor in India.

Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full year ended June 30, 2023.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-15, 2023.